Endometriosis is a benign gynecological condition prevalent among reproductive-aged women. Although active research and studies have been carried out to discover new drugs, surgery and hormone therapy are still the gold standard for endometriosis treatment. Nowadays, various flavonoids are considered long-term supplements for different diseases. Myricetin, a flavonol, has antiproliferative, anti- or pro-oxidant, and anticancer effects in gynecological diseases. Here, we reveal for the first time, to our knowledge, the antigrowth effects of myricetin in endometriosis. Myricetin inhibited cell proliferation and cell cycle progression of human VK2/E6E7 and End1/E6E7 cells and induced apoptosis, with the loss of mitochondrial membrane potential and accumulation of reactive oxygen species and calcium ions. Additionally, myricetin decreased the activation of AKT and ERK1/2 proteins, whereas it induced p38 activation in both cell lines. Moreover, myricetin decreased lesion size in the endometriosis mouse model via Ccne1 inhibition. Thus, myricetin has antiproliferative effects on endometriosis through cell cycle regulation.

子宫内膜异位是在生殖年龄妇女中普遍存在的良性妇科疾病。尽管已经进行了积极的研究以发现新药，但是手术和激素疗法仍然是子宫内膜异位症治疗的金标准。如今，各种类黄酮被认为是针对不同疾病的长期补品。杨梅素是一种黄酮醇，在妇科疾病中具有抗增殖，抗氧化剂或促氧化剂作用，并具有抗癌作用。据我们所知，在这里，我们首次揭示了杨梅素在子宫内膜异位症中的抗生长作用。杨桃素抑制人VK2 / E6E7和End1 / E6E7细胞的增殖和细胞周期进程，并诱导细胞凋亡，从而丧失线粒体膜电位以及活性氧和钙离子的积累。此外，杨梅素降低了AKT和ERK1 / 2蛋白的活化，而在两种细胞系中均诱导了p38活化。此外，杨梅素减少子宫内膜异位症小鼠模型中的病变大小通过Ccne1抑制。因此，杨梅素通过细胞周期调节对子宫内膜异位具有抗增殖作用。